Thirty-day outcomes of a novel biomimetic balloon-expandable transcatheter heart valve in patients with small aortic annuli
In patients with SAA, the DurAVR THV demonstrated promising clinical and echocardiographic outcomes at 30 days. Longer-term follow-up in larger cohorts is needed to confirm these encouraging early results.
Authors
- Amar Krishnaswamy (ORCID: https://orcid.org/0000-0001-6048-7955)
- Arif Khokhar (ORCID: https://orcid.org/0000-0002-4455-2865)
- Gintautas Bieliauskas (ORCID: https://orcid.org/0000-0002-4509-6654)
- Teona Zirakashvili
- Santiago García (ORCID: https://orcid.org/0000-0003-3715-8082)
- Ole De Backer (ORCID: https://orcid.org/0000-0002-9674-0278)
- Anita Asgar (ORCID: https://orcid.org/0000-0001-7308-2332)
- Vinayak Bapat (ORCID: https://orcid.org/0000-0002-2579-6434)
- João L. Cavalcante (ORCID: https://orcid.org/0000-0002-3632-2074)
- Stephan Windecker (ORCID: https://orcid.org/0000-0003-2653-6762)
- Azeem Latib (ORCID: https://orcid.org/0000-0001-9035-343X)
- Won‐Keun Kim (ORCID: https://orcid.org/0000-0003-3178-8569)
- Kari Feldt (ORCID: https://orcid.org/0000-0003-1013-7281)
- Thomas Waggoner
- Stanley Chetcuti
- Jeffrey J. Popma
- Rebecca T Hahn (ORCID: https://orcid.org/0000-0003-1342-9191)
- Michael J. Reardon (ORCID: https://orcid.org/0000-0002-2880-6132)
- Rishi Puri (ORCID: https://orcid.org/0000-0001-8849-7426)
- David Meier (ORCID: https://orcid.org/0000-0003-1662-2536)
- Augustin Coisne (ORCID: https://orcid.org/0000-0002-1662-7874)
- Maia Zhividze
- Gorav Ailawadi
- Christopher Meduri
- Paul Mahoney
- Tamaz Shaburishvili
Institutions
- University of Bern (CH)
- Houston Methodist (US)
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Abbott Northwestern Hospital (US)
- Allina Health (US)
- Karolinska University Hospital (SE)
- Montefiore Medical Center (US)
- Inserm (FR)
- East Carolina University (US)
- Justus-Liebig-Universität Gießen (DE)
- University of Michigan (US)
- Columbia University Irving Medical Center (US)
- Texas Health Dallas (US)
- Institut Pasteur de Lille (FR)
- University Hospital of Bern (CH)
- Tucson Medical Center (US)
- Rigshospitalet (DK)
- Koronis Biomedical Technologies (United States) (US)
- United Heart and Vascular Clinic (US)
- The Stern Cardiovascular Foundation (US)
- University of Minnesota Health Maple Grove Clinics (US)
- Cardiovascular Research Foundation (US)
- Northwestern Medicine (US)
- Christ Hospital (US)
- Medical Technologies (Czechia) (CZ)
- University of Lausanne (CH)
Publication Details
- Journal
- EuroIntervention
- Published
- 2026-01-27
- DOI
- https://doi.org/10.4244/eij-d-25-01106
- Citations
- 3
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 90.20
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Northwestern University
- Cleveland Clinic
- Minneapolis Heart Institute
- CSL Behring
- Boston Scientific Corporation
- University of Bern
- Amicus Therapeutics
- Université de Lille
- Abbott Northwestern Hospital Foundation
- Inselspital, Universitätsspital Bern
- JenaValve
- Abiomed
- Institut National de la Santé et de la Recherche Médicale
- Karolinska Institutet
- Novo Nordisk
- Université de Lausanne
- Centre Hospitalier Universitaire Vaudois
- Siemens Healthineers
- Servier
- Houston Methodist Research Institute
- Daiichi Sankyo Europe